Interventional Oncology for Small Liver, Kidney, and Lung Tumors: Current Evidence and Emerging Treatment Strategies

Image-guided ablation can treat small tumors while limiting tissue loss, but its clinical value also depends on the burden imposed on patients. This critical narrative review examines imaging, treatment selection, comparative outcomes, and follow-up for liver, renal, and lung tumors. A PubMed search, citation tracking, and targeted guideline and primary-study checks informed a nonexhaustive synthesis. Randomized evidence supports ablation in defined hepatocellular carcinoma and colorectal liver metastasis populations, subject to trial eligibility and stopping rules. Renal and pulmonary comparisons remain predominantly observational; partial nephrectomy, contemporary lung-sparing surgery, surveillance, and stereotactic radiotherapy provide distinct alternatives. Tumor biology, achievable margins, adjacent structures, functional reserve, competing mortality, and patient preferences are more informative than diameter alone. Protective maneuvers can improve access in selected anatomically difficult cases. Hepatic irreversible electroporation and histotripsy broaden technical possibilities, but their oncological evidence and safety constraints require careful interpretation. Technical success, follow-up efficacy, retreatment, survival, and functional outcomes must be reported separately. Prospective comparisons should measure durable cancer control alongside anesthesia, hospital use, recovery, quality of life, and cumulative treatment burden. Treatment selection should integrate these outcomes through shared decision-making.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-20
DOI
https://doi.org/10.3390/jcm15229094
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interventional Oncology for Small Liver, Kidney, and Lung Tumors: Current Evidence and Emerging Treatment Strategies

Carolina Lanza, Velio Ascenti, Pierluca Torcia, Pierpaolo Biondetti et al.
1 links
Journal of Clinical Medicine
Hepatocellular Carcinoma Treatment and Prognosis
article

Interventional Oncology for Small Liver, Kidney, and Lung Tumors: Current Evidence and Emerging Treatment Strategies

Carolina Lanza, Velio Ascenti, Pierluca Torcia, Pierpaolo Biondetti, Salvatore Alessio Angileri, Anna Maria Ierardi, Serena Carriero, Irene Carmen Pizza, Martina Pedullà, Jacopo Pozzi, Jacopo D’Argenzio, Desire’E Eboli, Paolo Mastromarino, Gianpaolo Carrafiello
article en

Abstract

Image-guided ablation can treat small tumors while limiting tissue loss, but its clinical value also depends on the burden imposed on patients. This critical narrative review examines imaging, treatment selection, comparative outcomes, and follow-up for liver, renal, and lung tumors. A PubMed search, citation tracking, and targeted guideline and primary-study checks informed a nonexhaustive synthesis. Randomized evidence supports ablation in defined hepatocellular carcinoma and colorectal liver metastasis populations, subject to trial eligibility and stopping rules. Renal and pulmonary comparisons remain predominantly observational; partial nephrectomy, contemporary lung-sparing surgery, surveillance, and stereotactic radiotherapy provide distinct alternatives. Tumor biology, achievable margins, adjacent structures, functional reserve, competing mortality, and patient preferences are more informative than diameter alone. Protective maneuvers can improve access in selected anatomically difficult cases. Hepatic irreversible electroporation and histotripsy broaden technical possibilities, but their oncological evidence and safety constraints require careful interpretation. Technical success, follow-up efficacy, retreatment, survival, and functional outcomes must be reported separately. Prospective comparisons should measure durable cancer control alongside anesthesia, hospital use, recovery, quality of life, and cumulative treatment burden. Treatment selection should integrate these outcomes through shared decision-making.

Journal of Clinical MedicineVol. 15(22)
University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon